Collegium Pharmaceutical COLL Insider Ownership

Updated Oct 10, 2026

Across the past 12 months, open-market trades by Collegium Pharmaceutical insiders were all sales, totaling $7.25 million (173.63K shares).

• Behind Collegium Pharmaceutical's open-market sales in the past 12 months were 8 insiders, and no insider bought.
• The largest open-market sales of COLL in the past 12 months were by Scott Dreyer (EVP & Chief Commercial Officer), totaling $2.87 million (67.58K shares), most recently on March 3, 2026.
• The latest open-market trade in COLL stock by an insider was a sale of 20 shares for $681 by John Gordon Freund (Director) on May 18, 2026.
• Away from the open market, COLL insiders received 315.14K shares in stock awards, acquired 78.55K shares through option exercises and conversions and gave up 119.47K shares to cover taxes or exercise prices over the last 12 months.
• Per Business Quant data, Collegium Pharmaceutical insiders hold 4.37Mn shares in total based on their latest Form 4 filings, or 13.46% of the 32.5Mn shares outstanding; that total is unchanged from 4.37Mn shares at the end of Q2 2026.
• Of the 4.37Mn shares held by Collegium Pharmaceutical insiders, 1.21Mn shares (27.65%) are held directly and 3.16Mn shares (72.35%) indirectly, through trusts, partnerships, family members and other entities.
• The insider holdings in Collegium Pharmaceutical belong to 16 insiders who have reported on Form 4 within the past two years.
• Collegium Pharmaceutical's top three insider holders by shares held are Rubric Capital Management LP (10% owner, 3.13Mn shares), Vikram Karnani (President and CEO, 197.86K shares) and Colleen Tupper (EVP & Chief Financial Officer, 147.28K shares).
• Rubric Capital Management LP holds 71.63% of the combined insider position in Collegium Pharmaceutical.
• Over the trailing 12 months, 13 insiders reported transactions in COLL stock across 25 Form 4 filings.
• This summary of Collegium Pharmaceutical insider activity covers Form 4 filings through June 10, 2026.